Drugs / PRA-216
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07245368 | Nov 2025 → Oct 2026 expected | asthma | Prana Therapies Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRA-216 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07245368 ↗ |
| Route | Intravenous | “administered by either intravenous (IV) or subcutaneous (SC).” NCT07245368 ↗ |
| Route | Subcutaneous | “administered by either intravenous (IV) or subcutaneous (SC).” NCT07245368 ↗ |